Carl Icahn Affiliates Approve Viskase Merger and Charter Amendment
Summary
Carl C. Icahn's affiliates, holding a 48.6% stake, formally approved the merger with Viskase and the related amendment to the company's certificate of incorporation.
Key Events
-
Major Shareholder Approves Merger
Carl C. Icahn's affiliates, holding 48.6% of outstanding shares, provided written consent approving the merger with Viskase.
-
Approves Charter Amendment
The consent also includes approval for an amendment to Enzon Pharmaceuticals' certificate of incorporation, likely related to the reverse stock split.
-
Critical Step for Merger Completion
This formal approval from a near-controlling shareholder significantly advances the merger process, which was recently detailed in definitive prospectus filings.
Analysis
This Schedule 13D/A filing indicates that affiliates of Carl C. Icahn, who collectively own 48.6% of Enzon Pharmaceuticals, have formally delivered written consent approving the company's proposed merger with Viskase and the associated amendment to the certificate of incorporation. This action is a critical step in the merger process, especially given Icahn's near-controlling stake. It significantly de-risks the transaction, which has been detailed in recent S-4 and 424B3 filings, by securing the necessary major shareholder approval. The approval of the charter amendment is also crucial, likely pertaining to the previously disclosed 1-for-100 reverse stock split.
At the time of this filing, ENZN was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.03 to $0.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.